嵌合抗原受体T细胞治疗原发性肝癌的研究进展  

Research progress of chimeric antigen receptor T cells in the treatment of primary liver cancer

作　　者：许洋[1] 张雅敏[2] 王建[2] 刘子荣[2] XU Yang;ZHANG Ya-min;WANG Jian;LIU Zi-rong(the First Central Clinical College of Tianjin Medical University,Tianjin 300070;Dept of Hepatobiliary Surgery,Tianjin First Central Hospital,Tianjin 300192,China)

机构地区：[1]天津医科大学第一中心临床学院,天津300070 [2]天津市第一中心医院肝胆外科,天津300192

出　　处：《基础医学与临床》2018年第7期1016-1019,共4页Basic and Clinical Medicine

基　　金：国家自然科学基金(81370576)

摘　　要：CAR-T技术作为免疫治疗的一种,从最早期的第一代发展至目前的第4代,其细胞毒性和抗肿瘤免疫效应大大增强,但也暴露出相关安全问题,其在原发性肝癌治疗的相关研究中展现出一定优势,预示着在精准个体化肝癌治疗时代,免疫治疗尤其CAR-T技术联合手术治疗、放化疗和局部治疗等综合治入将会发挥更强有力的作用。CAR-T technology as a kind of immunotherapy,from the earliest generation of the first to the current fourth generation,its cytotoxic,anti-tumor immune effect greatly enhanced,but also challenged by safety issues.It shows a certain advantage in the therapy of Hepatocellular carcinoma.It indicates that the era of precise individualized liver cancer treatment,immune therapy,especially CAR-T technology combined with surgery,radiotherapy and chemotherapy,local treatment and other comprehensive treatment will play a more powerful role.

关 键 词：原发性肝癌 免疫治疗 CAR-T疗法 靶点抗原 

分 类 号：R735.7[医药卫生—肿瘤]